-
公开(公告)号：US20240083995A1
公开(公告)日：2024-03-14
申请号：US18280100
申请日：2022-03-02
CPC分类号： C07K16/244 , A61K45/06 , A61P7/00
摘要： The present invention relates, in part, to methods for treating red blood cell disorders, such as an MDS and/or an anemia, by down-regulating IL-22 signaling.
-
2.发明授权Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity 有权通过调节XBP-1活性调节从头肝脂肪生成的方法公开(公告)号：US08940479B2
公开(公告)日：2015-01-27
申请号：US12812811
申请日：2009-01-14
申请人： Ann-Hwee Lee , Laurie H. Glimcher
发明人： Ann-Hwee Lee , Laurie H. Glimcher
IPC分类号： C12Q1/68 , A61K31/70 , C12N15/113
CPC分类号： A61K31/70 , C12N15/113 , C12N2310/14 , G01N2333/4703 , G01N2500/04 , G01N2800/044
摘要： The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.
摘要翻译： 本发明提供用于调节涉及XBP-1的信号转导途径中XBP-1蛋白或蛋白质的表达，加工，翻译后修饰，稳定性和/或活性以治疗血脂异常和脂肪变性障碍的方法和组合物。 本发明还涉及用于鉴定调节XBP-1蛋白或涉及XBP-1的信号转导途径中XBP-1蛋白或分子的表达，加工，翻译后修饰和/或活性的化合物的方法。
-
3.发明申请公开(公告)号：US20100242124A1
公开(公告)日：2010-09-23
申请号：US12730985
申请日：2010-03-24
CPC分类号： G01N33/505 , A01K67/0276 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/0331 , A01K2267/035 , A61K35/741 , A61K48/005 , C07K14/4702 , C12N15/8509 , G01N33/57419 , G01N33/6872 , G01N2500/10 , G01N2800/065 , G01N2800/50
摘要： The instant invention is based, at least in part, on the discovery that T-bet maintains host commensal relationships in the gastrointestinal tract. Accordingly, this invention provides methods of treating and/or preventing ulcerative colitis, and/or colon cancer, and/or preventing colonization of a subject's gastrointestinal tract with commensal bacteria that promote ulcerative colitis as well as methods of identifying agents that treat and prevent the same.
摘要翻译： 本发明至少部分地基于T-bet在胃肠道中维持宿主共同关系的发现。 因此，本发明提供治疗和/或预防溃疡性结肠炎和/或结肠癌的方法，和/或防止受体胃肠道与促进溃疡性结肠炎的共生细菌的定居，以及鉴定治疗和预防溃疡性结肠炎的药物的方法 相同。
-
4.发明申请METHODS FOR MODULATING BONE FORMATION AND MINERALIZATION BY MODULATING KRC ACTIVITY 有权通过调节KRC活性调节骨形成和矿化的方法公开(公告)号：US20090318338A1
公开(公告)日：2009-12-24
申请号：US11918503
申请日：2006-04-14
申请人： Laurie H. Glimcher , Dallas C. Jones , Marc Wein
发明人： Laurie H. Glimcher , Dallas C. Jones , Marc Wein
CPC分类号： C12N15/113 , C07K14/47 , C12N2310/14
摘要： This invention demonstrates that KRC molecules have multiple important functions as modulating agents in regulating a wide variety of cellular processes including bone formation and mineralization. TGF-β signaling in osteoblasts promotes the formation of a multimeric complex between KRC, Runx2, Smad3, and the E3 ubiquitin ligase, WWP1 which inhibits Runx2 function due to the ability of WWP1 to promote Runx2 polyubiquitination and proteasome-dependent degradation. Furthermore, KRC and WWP1 form a complex with RSK2 which promotes RSK2 phosphorylation and inhibits RSK2 function due to the ability of WWP 1 to promote RSK2 ubiquitination. Methods for identifying modulators of KRC activity are provided. Methods for modulating an immune response, bone formation and mineralization, and KRC-associated disorders using agents that modulate KRC expression and/or activity are also provided.
摘要翻译： 本发明表明，KRC分子在调节多种细胞过程（包括骨形成和矿化）中具有多种重要功能作为调节剂。 成骨细胞中的TGF-β信号促进KRC，Runx2，Smad3和E3泛素连接酶WWP1之间的多聚体复合物的形成，WWP1由于WWP1促进Runx2多聚泛素化和蛋白酶体依赖性降解的能力而抑制Runx2功能。 此外，KRC和WWP1与RSK2形成复合物，其促进RSK2磷酸化并且由于WWP1促进RSK2泛素化的能力而抑制RSK2功能。 提供了确定KRC活动调节剂的方法。 还提供了使用调节KRC表达和/或活性的试剂调节免疫应答，骨形成和矿化以及KRC相关疾病的方法。
-
5.发明授权Methods and compositions for regulating T cell subsets by modulating transcription factor activity 失效通过调节转录因子活性来调节T细胞亚群的方法和组合物公开(公告)号：US06967077B1
公开(公告)日：2005-11-22
申请号：US09248756
申请日：1999-02-12
申请人： Laurie H. Glimcher , I-Cheng Ho
发明人： Laurie H. Glimcher , I-Cheng Ho
IPC分类号： A61K38/00 , C07K14/47 , C07K14/52 , C07K14/54 , C07K14/82 , C12N15/12 , C12N15/00 , C07H21/04 , C12N15/09 , C12N15/86 , C12Q1/68
CPC分类号： A61K38/1709 , A01K2217/05 , A61K48/00 , C07K14/4702 , C07K14/52 , C07K14/5406 , C07K14/82 , C07K2319/00 , G01N33/505
摘要： Methods for modulating production of a T helper type 2 (Th2)-associated cytokine, in particular interleukin-4, by modulating the activity of a transcription factor, in particular the proto-oncoprotein c-Maf, that regulates expression of the Th2-associated cytokine gene are disclosed. Methods for modulating development of T helper type 1 (Th1) or T helper type 2 (Th2) subsets in a subject using agents that modulate transcription factor activity are also disclosed. The methods of the invention can further involve use of agents that modulate the activity of additional transcription factors that contribute to the regulation of Th1- or Th2-associated cytokines, such as a Nuclear Factor of Activated T cells (NF-AT) protein and/or an AP-1 family protein. Compositions for modulating Th2-associated cytokine production, recombinant expression vectors and host cells, as well as screening assays to identify agents that modulate c-Maf activity, are also disclosed.
摘要翻译： 通过调节调节Th2相关表达的转录因子，特别是原癌蛋白c-Maf的活性来调节T辅助2型（Th2）相关细胞因子特别是白细胞介素-4的产生的方法 公开了细胞因子基因。 还公开了使用调节转录因子活性的试剂调节受试者中T辅助性1型（Th1）或T辅助2型（Th2）亚型的发展的方法。 本发明的方法还可以包括使用调节有助于调节Th1或Th2相关细胞因子（例如活化T细胞核因子（NF-AT）蛋白）和/ 或AP-1家族蛋白。 还公开了用于调节Th2相关细胞因子产生的组合物，重组表达载体和宿主细胞，以及用于鉴定调节c-Maf活性的药剂的筛选测定。
-
公开(公告)号：US06410261B1
公开(公告)日：2002-06-25
申请号：US08965272
申请日：1997-11-06
申请人： Laurie H. Glimcher , Hong Zhou
发明人： Laurie H. Glimcher , Hong Zhou
IPC分类号： C07H2102
摘要： Isolated nucleic acid molecules encoding a novel protein, CIP104, that interacts with CIITA, an MHC class II transcriptional activator, are disclosed. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a CIP104 transgene. The invention further provides isolated CIP104 proteins and peptides, CIP104 fusion proteins and anti-CIP104 antibodies. Methods of using the CIP104 compositions of the invention are also disclosed, including methods for detecting CIP104 activity (e.g., CIP104 protein or mRNA) in a biological sample, methods of modulating CIP104 activity in a cell, and methods for identifying agents that modulate an interaction between CIP104 and CIITA.
-
公开(公告)号：US6149905A
公开(公告)日：2000-11-21
申请号：US159135
申请日：1998-09-23
申请人： Suzanne Ostrand-Rosenberg , Sivasubramanian Baskar , Laurie H. Glimcher , Gordon J. Freeman , Lee M. Nadler
发明人： Suzanne Ostrand-Rosenberg , Sivasubramanian Baskar , Laurie H. Glimcher , Gordon J. Freeman , Lee M. Nadler
IPC分类号： A61K39/00 , A61K48/00 , C07K14/705 , C07K14/74 , C12N5/08
CPC分类号： A61K39/0011 , C07K14/70532 , C07K14/70539 , A61K2039/5152 , A61K2039/5156 , A61K2039/5158 , A61K39/00 , A61K48/00
摘要： Tumor cells modified to express a T cell costimulatory molecule are disclosed. In one embodiment, the costimulatory molecule is a CD28/CTLA4 ligand, preferably a B lymphocyte antigen B7. The tumor cells of the invention can be modified by transfection with nucleic acid encoding a T cell costimulatory molecule, by using an agent which induces or increases expression of a T cell costimulatory molecule on the tumor cell surface or by coupling a T cell costimulatory molecule to the tumor cell surface. Tumor cells further modified to express MHC class I and/or class II molecules or in which expression of an MHC associated protein, the invariant chain, is inhibited are also disclosed. The modified tumor cells of the invention can be used in methods for treating a patient with a tumor, preventing or inhibiting metastatic spread of a tumor or preventing or inhibiting recurrence of a tumor. A method for specifically inducing a CD4.sup.+ T cell response against a tumor and a method for treating a tumor by modification of tumor cells in vivo are disclosed.
-
8.发明授权Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer and screening methods to identify same 有权用于治疗和预防溃疡性结肠炎和结肠癌的组合物和方法以及筛选方法进行鉴定公开(公告)号：US08389792B2
公开(公告)日：2013-03-05
申请号：US12730985
申请日：2010-03-24
CPC分类号： G01N33/505 , A01K67/0276 , A01K2217/075 , A01K2217/15 , A01K2227/105 , A01K2267/0331 , A01K2267/035 , A61K35/741 , A61K48/005 , C07K14/4702 , C12N15/8509 , G01N33/57419 , G01N33/6872 , G01N2500/10 , G01N2800/065 , G01N2800/50
摘要： The instant invention is based, at least in part, on the discovery that T-bet maintains host commensal relationships in the gastrointestinal tract. Accordingly, this invention provides methods of treating and/or preventing ulcerative colitis, and/or colon cancer, and/or preventing colonization of a subject's gastrointestinal tract with commensal bacteria that promote ulcerative colitis as well as methods of identifying agents that treat and prevent the same.
摘要翻译： 本发明至少部分地基于T-bet在胃肠道中维持宿主共同关系的发现。 因此，本发明提供治疗和/或预防溃疡性结肠炎和/或结肠癌的方法，和/或防止受体胃肠道与促进溃疡性结肠炎的共生细菌的定居，以及鉴定治疗和预防溃疡性结肠炎的药物的方法 相同。
-
公开(公告)号：US20120159661A1
公开(公告)日：2012-06-21
申请号：US13285708
申请日：2011-10-31
IPC分类号： A01K67/027 , C12N5/071 , A61K39/395 , A61P11/06 , C12Q1/68 , G01N33/566 , C12N5/10 , A61K31/7088
CPC分类号： C07K14/4705 , A01K2217/05 , A61K38/00 , C07K2319/00 , G01N33/6866 , G01N33/6869 , G01N33/6872 , G01N33/6875 , G01N33/74 , G01N2500/00
摘要： Isolated nucleic acid molecules encoding T-bet, and isolated T-bet polypeptides, are provided. The invention further provides antisense nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals carrying a T-bet transgene. The invention further provides T-bet fusion proteins and anti-T-bet antibodies. Methods of using the T-bet compositions of the invention are also disclosed, including methods for detecting T-bet expression and/or activity in a biological sample, methods of modulating T-bet expression and/or activity in a cell, and methods for identifying agents that modulate the expression and/or activity of T-bet.
摘要翻译： 提供编码T-bet和分离的T-bet多肽的分离的核酸分子。 本发明进一步提供反义核酸分子，含有本发明的核酸分子的重组表达载体，已经引入了表达载体的宿主细胞和携带T-bet转基因的非人转基因动物。 本发明还提供了T-bet融合蛋白和抗T-bet抗体。 还公开了使用本发明的T-bet组合物的方法，包括用于检测生物样品中T-bet表达和/或活性的方法，调节细胞中T-bet表达和/或活性的方法，以及用于 识别调节T-bet的表达和/或活性的试剂。
-
10.发明申请METHODS FOR MODULATING DE NOVO HEPATIC LIPOGENESIS BY MODULATING XBP-1 ACTIVITY 有权通过调节XBP-1活性来调节去势血液生成的方法公开(公告)号：US20110052669A1
公开(公告)日：2011-03-03
申请号：US12812811
申请日：2009-01-14
申请人： Ann-Hwee Lee , Laurie H. Glimcher
发明人： Ann-Hwee Lee , Laurie H. Glimcher
IPC分类号： A61K9/127 , A61P3/06 , A61K31/7088 , A61P9/10 , A61P1/16 , A61K31/713 , C40B30/06
CPC分类号： A61K31/70 , C12N15/113 , C12N2310/14 , G01N2333/4703 , G01N2500/04 , G01N2800/044
摘要： The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1.
摘要翻译： 本发明提供用于调节涉及XBP-1的信号转导途径中XBP-1蛋白或蛋白质的表达，加工，翻译后修饰，稳定性和/或活性以治疗血脂异常和脂肪变性障碍的方法和组合物。 本发明还涉及用于鉴定调节XBP-1蛋白或涉及XBP-1的信号转导途径中XBP-1蛋白或分子的表达，加工，翻译后修饰和/或活性的化合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
53 条记录 (耗时 0.034 秒)
